
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis Inc is positioned favorably within the clinical-stage biopharmaceutical sector, focusing on innovative therapies for autoimmune disorders, underscoring its potential for significant market impact. The company has a clinical pipeline that includes promising candidates such as ESK-001, with conservative estimates projecting peak sales of $2 billion for systemic lupus erythematosus (SLE), despite a cautious 20% probability of approval suggesting substantial upside potential. The favorable comparisons to existing treatments and the strategic focus on targeted rather than broad immunosuppression indicate a significant opportunity for the company to capture a vital market share, reinforcing positive sentiment around its stock outlook.
Bears say
Alumis Inc faces several fundamental risks that contribute to a negative outlook on its stock, primarily revolving around the development and approval of its lead product, ESK-001. The inability to advance ESK-001 into pivotal trials within expected timelines, coupled with potential failures in demonstrating efficacy for psoriasis (PsO) and systemic lupus erythematosus (SLE), poses significant challenges to the company’s growth trajectory. Furthermore, delays in regulatory submissions and approvals, along with competitive pressures in the immunology and inflammation (I&I) market, may hinder market uptake while presenting risks of dilution to current investors.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares